Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance

Figure 3

The parameters of insulin sensitivity and adipose distribution among the pre- and post-6-month exenatide treatment and the following 6-month glargine treatment. Data are expressed as mean with standard deviation (SD) ( value < 0.05; value < 0.01). FINS: fasting serum insulin level; CP: fasting serum C-peptide level; HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-β: homeostatic model assessment of beta-cell function; TAT: total adipose tissue volumes; VAT: visceral adipose tissue volumes; SAT: subcutaneous adipose tissue volumes; VAT/SAT: ratio of visceral adipose tissue volumes (VAT) over subcutaneous adipose tissue volumes (SAT).